DK0010272202 - 565131 (XCSE)
GENMAB AS DK 1 Aktie
238,76 EUR
Aktuelle Kurse von GENMAB AS DK 1
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
Frankfurt |
GE9.F
|
EUR
|
19.09.2024 10:24
|
236,70 EUR
| 237,00 EUR | -0,13 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
-0,29 % | -0,98 % | -2,38 % | -1,08 % | -13,50 % | -33,75 % | 28,21 % |
Firmenprofil zu GENMAB AS DK 1 Aktie
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Investierte Fonds
Folgende Fonds haben in GENMAB AS DK 1 investiert:
Fonds | Vol. in Mio 832,16 | Anteil (%) 1,91 % |
Fonds | Vol. in Mio 1.158,01 | Anteil (%) 1,35 % |
Fonds | Vol. in Mio 110,52 | Anteil (%) 1,35 % |
Fonds | Vol. in Mio 175,99 | Anteil (%) 1,14 % |
Fonds | Vol. in Mio 7.713,76 | Anteil (%) 1,10 % |
Unternehmensdaten zur GENMAB AS DK 1 Aktie
Name GENMAB AS DK 1
Firma Genmab A/S
Website https://www.genmab.com
Heimatbörse
NASDAQ COPENHAGEN A/S
WKN 565131
ISIN DK0010272202
Wertpapierart Aktie
CEO Dr. Jan G.J. van de Winkel Ph.D.
Marktkapitalisierung 17 Mrd.
Land Dänemark
Währung EUR
Mitarbeiter 2,3 T
Adresse Carl Jacobsens Vej 30, 2500 Copenhagen
IPO Datum 2000-10-23
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | GE9.F |
Weitere Aktien
Investoren die GENMAB AS DK 1 halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024